PulseSight Therapeutics: Nonviral Gene Therapy for Dry AMD
With a novel electro-transfection technology PulseSight targets difficult-to-treat ocular diseases. The start-up’s platform has the potential to realize the benefits of gene therapy and large molecule injections while avoiding the drawbacks.
Read Article